Delcath Systems Inc (DCTH) Q1 2026 Earnings Call Transcript

Why It Matters

The stronger revenue trajectory and expanding clinical uptake position Delcath to achieve its $100 million goal and generate positive cash flow, while the cash cushion and share buy‑backs underscore financial resilience amid rising R&D and SG&A spend.

Key Takeaways

• Revenue hit $25M, up 26% YoY.
• HEPZATO kit volume grew mid‑20% QoQ.
• New patient starts per site reached record 0.7/month.
• Activated sites guidance lowered to 37, 40 by Q1‑27.
• Adjusted EBITDA expected positive for remainder of 2026.

Pulse Analysis

The percutaneous hepatic perfusion (PHP) platform, marketed as HEPZATO, occupies a niche in liver‑directed oncology where systemic toxicity limits traditional chemotherapy. The recent CHOPIN trial, which combined HEPZATO with checkpoint inhibitors, demonstrated response rates climbing from roughly 40% to 76% and a clear survival advantage at one and two years. Those data have already shifted prescribing behavior at both established and newly certified REMS sites, fueling a mid‑20% quarter‑over‑quarter kit volume surge. As physicians observe tangible tumor shrinkage, the therapy is gaining traction not only for metastatic uveal melanoma but also for off‑label exploration in colorectal and breast liver metastases.

Financially, Delcath delivered $25 million of revenue in Q1, surpassing the $19.8 million recorded a year earlier, while maintaining gross margins in the mid‑80% range. Adjusted EBITDA of $3.4 million, though down from the prior year, is expected to turn positive for the balance of 2026 as higher patient volumes offset the slower rollout of new sites. The company’s balance sheet remains robust, with $89.3 million in cash and no debt, providing ample runway for the planned 70‑75% increase in R&D spend and a 60% rise in SG&A. A $3 million share repurchase this quarter signals confidence in capital allocation.

Looking ahead, Delcath’s growth hinges on accelerating the activation of REMS‑certified centers and strengthening referral pathways that funnel eligible patients to treatment hubs. Management has revised the year‑end active‑site target to 37, but anticipates higher per‑site utilization to compensate, a strategy supported by the fully deployed Medical Science Liaison team. European expansion remains modest due to reimbursement hurdles, yet the region offers a valuable source of real‑world data for upcoming trials. With colorectal and breast cancer programs entering later‑stage enrollment, the company is positioning HEPZATO as a platform therapy that could unlock additional indications and sustain long‑term revenue momentum.